Skip to main content
Erschienen in: Osteoporosis International 12/2015

01.12.2015 | Original Article

Low vitamin D levels have become less common in primary hyperparathyroidism

verfasst von: M. D. Walker, E. Cong, J. A. Lee, A. Kepley, C. Zhang, D. J. McMahon, J. P. Bilezikian, S. J. Silverberg

Erschienen in: Osteoporosis International | Ausgabe 12/2015

Einloggen, um Zugang zu erhalten

Abstract

Summary

We compared temporal trends in serum 25-hydroxyvitamin D and parathyroid hormone (PTH) in two primary hyperparathyroidism (PHPT) cohorts recruited 20 years apart. The prevalence of 25-hydroxyvitamin D levels <20 and <30 ng/mL declined by 30–50 %, respectively, and was accompanied by lower PTH. In the older cohort, higher PTH may be due to lower 25-hydroxyvitamin D.

Introduction

Vitamin D deficiency may exacerbate PHPT. Whether there have been temporal trends in 25-hydroxyvitamin D (25OHD) levels in PHPT is unclear. The prevalence of low vitamin D levels (25OHD <20 and <30 ng/mL) and associated biochemical and bone mineral density (BMD) profiles were assessed in two PHPT cohorts recruited over 20 years apart.

Methods

This is a cross-sectional comparison of serum 25OHD levels, calciotropic hormones, and BMD between two PHPT cohorts recruited at the same hospital: the “old” (N = 103) and “new” (N = 100) cohorts were enrolled between 1984 and 1991 and between 2010 and 2014, respectively.

Results

Mean 25OHD levels were 26 % higher in the new cohort (23 ± 10 vs. 29 ± 10 ng/mL, p < 0.0001). Levels of 25OHD <20 and <30 ng/mL declined from 46 and 82 %, respectively, to 19 and 54 % (both p < 0.0001). Supplemental vitamin D use was common in the new (64 %) but not the old cohort (0 %). The new cohort demonstrated 33 % lower serum PTH levels (p < 0.0001). Neither serum nor urine calcium differed. BMD was higher in the new cohort at all skeletal sites (all p < 0.001).

Conclusion

With the rise in vitamin D supplementation over the last two decades, low 25OHD levels are no longer common in PHPT patients in the New York area. Those with 25OHD <20 and <30 ng/mL have declined by over 50 and 30 %, respectively. The lower mean PTH levels in the new cohort are most likely accounted for by higher vitamin D intake. Whether improved vitamin D status also underlies the relatively higher BMD in the more vitamin D replete cohort of PHPT patients is unknown.
Literatur
1.
Zurück zum Zitat Moosgaard B, Vestergaard P, Heickendorff L, Melsen F, Christiansen P, Mosekilde L (2005) Vitamin D status, seasonal variations, parathyroid adenoma weight and bone mineral density in primary hyperparathyroidism. Clin Endocrinol (Oxf) 63:506–513CrossRef Moosgaard B, Vestergaard P, Heickendorff L, Melsen F, Christiansen P, Mosekilde L (2005) Vitamin D status, seasonal variations, parathyroid adenoma weight and bone mineral density in primary hyperparathyroidism. Clin Endocrinol (Oxf) 63:506–513CrossRef
2.
Zurück zum Zitat Boudou P, Ibrahim F, Cormier C, Sarfati E, Souberbielle JC (2006) A very high incidence of low 25 hydroxy-vitamin D serum concentration in a French population of patients with primary hyperparathyroidism. J Endocrinol Invest 29:511–515CrossRefPubMed Boudou P, Ibrahim F, Cormier C, Sarfati E, Souberbielle JC (2006) A very high incidence of low 25 hydroxy-vitamin D serum concentration in a French population of patients with primary hyperparathyroidism. J Endocrinol Invest 29:511–515CrossRefPubMed
3.
Zurück zum Zitat Clements MR, Davies M, Hayes ME, Hickey CD, Lumb GA, Mawer EB, Adams PH (1992) The role of 1,25-dihydroxyvitamin D in the mechanism of acquired vitamin D deficiency. Clin Endocrinol (Oxf) 37:17–27CrossRef Clements MR, Davies M, Hayes ME, Hickey CD, Lumb GA, Mawer EB, Adams PH (1992) The role of 1,25-dihydroxyvitamin D in the mechanism of acquired vitamin D deficiency. Clin Endocrinol (Oxf) 37:17–27CrossRef
4.
Zurück zum Zitat Clements MR, Davies M, Fraser DR, Lumb GA, Mawer EB, Adams PH (1987) Metabolic inactivation of vitamin D is enhanced in primary hyperparathyroidism. Clin Sci (Lond) 73:659–664CrossRef Clements MR, Davies M, Fraser DR, Lumb GA, Mawer EB, Adams PH (1987) Metabolic inactivation of vitamin D is enhanced in primary hyperparathyroidism. Clin Sci (Lond) 73:659–664CrossRef
5.
Zurück zum Zitat Lumb GA, Stanbury SW (1974) Parathyroid function in human vitamin D deficiency and vitamin D deficiency in primary hyperparathyroidism. Am J Med 56:833–839CrossRefPubMed Lumb GA, Stanbury SW (1974) Parathyroid function in human vitamin D deficiency and vitamin D deficiency in primary hyperparathyroidism. Am J Med 56:833–839CrossRefPubMed
6.
Zurück zum Zitat Rao DS, Honasoge M, Divine GW, Phillips ER, Lee MW, Ansari MR, Talpos GB, Parfitt AM (2000) Effect of vitamin D nutrition on parathyroid adenoma weight: pathogenetic and clinical implications. J Clin Endocrinol Metab 85:1054–1058PubMed Rao DS, Honasoge M, Divine GW, Phillips ER, Lee MW, Ansari MR, Talpos GB, Parfitt AM (2000) Effect of vitamin D nutrition on parathyroid adenoma weight: pathogenetic and clinical implications. J Clin Endocrinol Metab 85:1054–1058PubMed
7.
Zurück zum Zitat Rao DS, Agarwal G, Talpos GB, Phillips ER, Bandeira F, Mishra SK, Mithal A (2002) Role of vitamin D and calcium nutrition in disease expression and parathyroid tumor growth in primary hyperparathyroidism: a global perspective. J Bone Miner Res 17(Suppl 2):N75–N80PubMed Rao DS, Agarwal G, Talpos GB, Phillips ER, Bandeira F, Mishra SK, Mithal A (2002) Role of vitamin D and calcium nutrition in disease expression and parathyroid tumor growth in primary hyperparathyroidism: a global perspective. J Bone Miner Res 17(Suppl 2):N75–N80PubMed
8.
Zurück zum Zitat Silverberg SJ, Shane E, Dempster DW, Bilezikian JP (1999) The effects of vitamin D insufficiency in patients with primary hyperparathyroidism. Am J Med 107:561–567CrossRefPubMed Silverberg SJ, Shane E, Dempster DW, Bilezikian JP (1999) The effects of vitamin D insufficiency in patients with primary hyperparathyroidism. Am J Med 107:561–567CrossRefPubMed
9.
Zurück zum Zitat Ozbey N, Erbil Y, Ademoglu E, Ozarmagan S, Barbaros U, Bozbora A (2006) Correlations between vitamin D status and biochemical/clinical and pathological parameters in primary hyperparathyroidism. World J Surg 30:321–326CrossRefPubMed Ozbey N, Erbil Y, Ademoglu E, Ozarmagan S, Barbaros U, Bozbora A (2006) Correlations between vitamin D status and biochemical/clinical and pathological parameters in primary hyperparathyroidism. World J Surg 30:321–326CrossRefPubMed
10.
Zurück zum Zitat Beyer TD, Chen EL, Nilubol N, Prinz RA, Solorzano CC (2007) Short-term outcomes of parathyroidectomy in patients with or without 25-hydroxy vitamin D insufficiency. J Surg Res 143:145–150CrossRefPubMed Beyer TD, Chen EL, Nilubol N, Prinz RA, Solorzano CC (2007) Short-term outcomes of parathyroidectomy in patients with or without 25-hydroxy vitamin D insufficiency. J Surg Res 143:145–150CrossRefPubMed
11.
Zurück zum Zitat Moosgaard B, Christensen SE, Vestergaard P, Heickendorff L, Christiansen P, Mosekilde L (2008) Vitamin D metabolites and skeletal consequences in primary hyperparathyroidism. Clin Endocrinol (Oxf) 68:707–715CrossRef Moosgaard B, Christensen SE, Vestergaard P, Heickendorff L, Christiansen P, Mosekilde L (2008) Vitamin D metabolites and skeletal consequences in primary hyperparathyroidism. Clin Endocrinol (Oxf) 68:707–715CrossRef
12.
Zurück zum Zitat Yamashita H, Noguchi S, Uchino S, Watanabe S, Koike E, Murakami T, Fujihira T, Koga Y, Masatsugu T, Yamashita H (2002) Vitamin D status in Japanese patients with hyperparathyroidism: seasonal changes and effect on clinical presentation. World J Surg 26:937–941CrossRefPubMed Yamashita H, Noguchi S, Uchino S, Watanabe S, Koike E, Murakami T, Fujihira T, Koga Y, Masatsugu T, Yamashita H (2002) Vitamin D status in Japanese patients with hyperparathyroidism: seasonal changes and effect on clinical presentation. World J Surg 26:937–941CrossRefPubMed
13.
Zurück zum Zitat Dickinson A, Blatman J, El-Dash N, Franco JC (2014) Consumer usage and reasons for using dietary supplements: report of a series of surveys. J Am Coll Nutr 33:176–182CrossRefPubMed Dickinson A, Blatman J, El-Dash N, Franco JC (2014) Consumer usage and reasons for using dietary supplements: report of a series of surveys. J Am Coll Nutr 33:176–182CrossRefPubMed
14.
Zurück zum Zitat Berger C, Greene-Finestone LS, Langsetmo L et al (2012) Temporal trends and determinants of longitudinal change in 25-hydroxyvitamin D and parathyroid hormone levels. J Bone Miner Res 27:1381–1389CrossRefPubMed Berger C, Greene-Finestone LS, Langsetmo L et al (2012) Temporal trends and determinants of longitudinal change in 25-hydroxyvitamin D and parathyroid hormone levels. J Bone Miner Res 27:1381–1389CrossRefPubMed
15.
Zurück zum Zitat Looker AC, Pfeiffer CM, Lacher DA, Schleicher RL, Picciano MF, Yetley EA (2008) Serum 25-hydroxyvitamin D status of the US population: 1988-1994 compared with 2000-2004. Am J Clin Nutr 88:1519–1527PubMedCentralCrossRefPubMed Looker AC, Pfeiffer CM, Lacher DA, Schleicher RL, Picciano MF, Yetley EA (2008) Serum 25-hydroxyvitamin D status of the US population: 1988-1994 compared with 2000-2004. Am J Clin Nutr 88:1519–1527PubMedCentralCrossRefPubMed
16.
Zurück zum Zitat Jorde R, Sneve M, Hutchinson M, Emaus N, Figenschau Y, Grimnes G (2010) Tracking of serum 25-hydroxyvitamin D levels during 14 years in a population-based study and during 12 months in an intervention study. Am J Epidemiol 171:903–908CrossRefPubMed Jorde R, Sneve M, Hutchinson M, Emaus N, Figenschau Y, Grimnes G (2010) Tracking of serum 25-hydroxyvitamin D levels during 14 years in a population-based study and during 12 months in an intervention study. Am J Epidemiol 171:903–908CrossRefPubMed
17.
Zurück zum Zitat Holick MF, Binkley NC, Bischoff-Ferrari HA, Gordon CM, Hanley DA, Heaney RP, Murad MH, Weaver CM (2011) Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 96:1911–1930CrossRefPubMed Holick MF, Binkley NC, Bischoff-Ferrari HA, Gordon CM, Hanley DA, Heaney RP, Murad MH, Weaver CM (2011) Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 96:1911–1930CrossRefPubMed
18.
Zurück zum Zitat Silverberg SJ, Shane E, Jacobs TP, Siris E, Bilezikian JP (1999) A 10-year prospective study of primary hyperparathyroidism with or without parathyroid surgery. N Engl J Med 341:1249–1255CrossRefPubMed Silverberg SJ, Shane E, Jacobs TP, Siris E, Bilezikian JP (1999) A 10-year prospective study of primary hyperparathyroidism with or without parathyroid surgery. N Engl J Med 341:1249–1255CrossRefPubMed
19.
Zurück zum Zitat Rubin MR, Bilezikian JP, McMahon DJ, Jacobs T, Shane E, Siris E, Udesky J, Silverberg SJ (2008) The natural history of primary hyperparathyroidism with or without parathyroid surgery after 15 years. J Clin Endocrinol Metab 93:3462–3470PubMedCentralCrossRefPubMed Rubin MR, Bilezikian JP, McMahon DJ, Jacobs T, Shane E, Siris E, Udesky J, Silverberg SJ (2008) The natural history of primary hyperparathyroidism with or without parathyroid surgery after 15 years. J Clin Endocrinol Metab 93:3462–3470PubMedCentralCrossRefPubMed
20.
Zurück zum Zitat Bilezikian JP, Khan AA, Potts JT Jr (2009) Guidelines for the management of asymptomatic primary hyperparathyroidism: summary statement from the third international workshop. J Clin Endocrinol Metab 94:335–339PubMedCentralCrossRefPubMed Bilezikian JP, Khan AA, Potts JT Jr (2009) Guidelines for the management of asymptomatic primary hyperparathyroidism: summary statement from the third international workshop. J Clin Endocrinol Metab 94:335–339PubMedCentralCrossRefPubMed
21.
Zurück zum Zitat Walker MD, Cong E, Kepley A et al (2014) Association between serum 25-hydroxyvitamin D level and subclinical cardiovascular disease in primary hyperparathyroidism. J Clin Endocrinol Metab 99:671–680PubMedCentralCrossRefPubMed Walker MD, Cong E, Kepley A et al (2014) Association between serum 25-hydroxyvitamin D level and subclinical cardiovascular disease in primary hyperparathyroidism. J Clin Endocrinol Metab 99:671–680PubMedCentralCrossRefPubMed
22.
Zurück zum Zitat Nussbaum SR, Zahradnik RJ, Lavigne JR, Brennan GL, Nozawa-Ung K, Kim LY, Keutmann HT, Wang CA, Potts JT Jr, Segre GV (1987) Highly sensitive two-site immunoradiometric assay of parathyrin, and its clinical utility in evaluating patients with hypercalcemia. Clin Chem 33:1364–1367PubMed Nussbaum SR, Zahradnik RJ, Lavigne JR, Brennan GL, Nozawa-Ung K, Kim LY, Keutmann HT, Wang CA, Potts JT Jr, Segre GV (1987) Highly sensitive two-site immunoradiometric assay of parathyrin, and its clinical utility in evaluating patients with hypercalcemia. Clin Chem 33:1364–1367PubMed
23.
Zurück zum Zitat Inaba M, Nakatsuka K, Imanishi Y, Watanabe M, Mamiya Y, Ishimura E, Nishizawa Y (2004) Technical and clinical characterization of the Bio-PTH (1-84) immunochemiluminometric assay and comparison with a second-generation assay for parathyroid hormone. Clin Chem 50:385–390CrossRefPubMed Inaba M, Nakatsuka K, Imanishi Y, Watanabe M, Mamiya Y, Ishimura E, Nishizawa Y (2004) Technical and clinical characterization of the Bio-PTH (1-84) immunochemiluminometric assay and comparison with a second-generation assay for parathyroid hormone. Clin Chem 50:385–390CrossRefPubMed
24.
Zurück zum Zitat Cantor T, Yang Z, Caraiani N, Ilamathi E (2006) Lack of comparability of intact parathyroid hormone measurements among commercial assays for end-stage renal disease patients: implication for treatment decisions. Clin Chem 52:1771–1776CrossRefPubMed Cantor T, Yang Z, Caraiani N, Ilamathi E (2006) Lack of comparability of intact parathyroid hormone measurements among commercial assays for end-stage renal disease patients: implication for treatment decisions. Clin Chem 52:1771–1776CrossRefPubMed
25.
Zurück zum Zitat Preece MA, O’Riordan JL, Lawson DE, Kodicek E (1974) A competitive protein-binding assay for 25-hydroxycholecalciferol and 25-hydroxyergocalciferol in serum. Clin Chim Acta 54:235–242CrossRefPubMed Preece MA, O’Riordan JL, Lawson DE, Kodicek E (1974) A competitive protein-binding assay for 25-hydroxycholecalciferol and 25-hydroxyergocalciferol in serum. Clin Chim Acta 54:235–242CrossRefPubMed
26.
Zurück zum Zitat Reinhardt TA, Horst RL, Orf JW, Hollis BW (1984) A microassay for 1,25-dihydroxyvitamin D not requiring high performance liquid chromatography: application to clinical studies. J Clin Endocrinol Metab 58:91–98CrossRefPubMed Reinhardt TA, Horst RL, Orf JW, Hollis BW (1984) A microassay for 1,25-dihydroxyvitamin D not requiring high performance liquid chromatography: application to clinical studies. J Clin Endocrinol Metab 58:91–98CrossRefPubMed
27.
Zurück zum Zitat Bonnick SL, Johnston CC Jr, Kleerekoper M, Lindsay R, Miller P, Sherwood L, Siris E (2001) Importance of precision in bone density measurements. J Clin Densitom 4:105–110CrossRefPubMed Bonnick SL, Johnston CC Jr, Kleerekoper M, Lindsay R, Miller P, Sherwood L, Siris E (2001) Importance of precision in bone density measurements. J Clin Densitom 4:105–110CrossRefPubMed
28.
Zurück zum Zitat Eastell R, Arnold A, Brandi ML et al (2009) Diagnosis of asymptomatic primary hyperparathyroidism: proceedings of the third international workshop. J Clin Endocrinol Metab 94:340–350CrossRefPubMed Eastell R, Arnold A, Brandi ML et al (2009) Diagnosis of asymptomatic primary hyperparathyroidism: proceedings of the third international workshop. J Clin Endocrinol Metab 94:340–350CrossRefPubMed
29.
Zurück zum Zitat Bilezikian JP, Brandi ML, Eastell R, Silverberg SJ, Udelsman R, Marcocci C, Potts JT Jr (2014) Guidelines for the management of asymptomatic primary hyperparathyroidism: summary statement from the fourth international workshop. J Clin Endocrinol Metab 99:3561–3569CrossRefPubMed Bilezikian JP, Brandi ML, Eastell R, Silverberg SJ, Udelsman R, Marcocci C, Potts JT Jr (2014) Guidelines for the management of asymptomatic primary hyperparathyroidism: summary statement from the fourth international workshop. J Clin Endocrinol Metab 99:3561–3569CrossRefPubMed
30.
Zurück zum Zitat Mitchell D, Lee H, Greendale G, Cauley JA, Burnett-Bowie S, Finkelstein JS (2014) Increasing 25-hydroxyvitamin D levels over time: the Study of Women’s Health Across the Nation (SWAN). In ASBMR, Houston, TX Mitchell D, Lee H, Greendale G, Cauley JA, Burnett-Bowie S, Finkelstein JS (2014) Increasing 25-hydroxyvitamin D levels over time: the Study of Women’s Health Across the Nation (SWAN). In ASBMR, Houston, TX
31.
Zurück zum Zitat Shah VN, Shah CS, Bhadada SK, Rao DS (2014) Effect of 25 (OH) D replacements in patients with primary hyperparathyroidism (PHPT) and coexistent vitamin D deficiency on serum 25(OH) D, calcium and PTH levels: a meta-analysis and review of literature. Clin Endocrinol (Oxf) Shah VN, Shah CS, Bhadada SK, Rao DS (2014) Effect of 25 (OH) D replacements in patients with primary hyperparathyroidism (PHPT) and coexistent vitamin D deficiency on serum 25(OH) D, calcium and PTH levels: a meta-analysis and review of literature. Clin Endocrinol (Oxf)
32.
Zurück zum Zitat Rao RR, Randeva HS, Sankaranarayanan S, Narashima M, Mohlig M, Mehanna H, Weickert MO (2012) Prolonged treatment with vitamin D in postmenopausal women with primary hyperparathyroidism. Endocr Connect 1:13–21PubMedCentralCrossRefPubMed Rao RR, Randeva HS, Sankaranarayanan S, Narashima M, Mohlig M, Mehanna H, Weickert MO (2012) Prolonged treatment with vitamin D in postmenopausal women with primary hyperparathyroidism. Endocr Connect 1:13–21PubMedCentralCrossRefPubMed
33.
Zurück zum Zitat Grey A, Lucas J, Horne A, Gamble G, Davidson JS, Reid IR (2005) Vitamin D repletion in patients with primary hyperparathyroidism and coexistent vitamin D insufficiency. J Clin Endocrinol Metab 90:2122–2126CrossRefPubMed Grey A, Lucas J, Horne A, Gamble G, Davidson JS, Reid IR (2005) Vitamin D repletion in patients with primary hyperparathyroidism and coexistent vitamin D insufficiency. J Clin Endocrinol Metab 90:2122–2126CrossRefPubMed
34.
Zurück zum Zitat Grubbs EG, Rafeeq S, Jimenez C, Feng L, Lee JE, Evans DB, Perrier ND (2008) Preoperative vitamin D replacement therapy in primary hyperparathyroidism: safe and beneficial? Surgery 144:852–858, discussion 858-859CrossRefPubMed Grubbs EG, Rafeeq S, Jimenez C, Feng L, Lee JE, Evans DB, Perrier ND (2008) Preoperative vitamin D replacement therapy in primary hyperparathyroidism: safe and beneficial? Surgery 144:852–858, discussion 858-859CrossRefPubMed
35.
Zurück zum Zitat Tucci JR (2009) Vitamin D therapy in patients with primary hyperparathyroidism and hypovitaminosis D. Eur J Endocrinol 161:189–193CrossRefPubMed Tucci JR (2009) Vitamin D therapy in patients with primary hyperparathyroidism and hypovitaminosis D. Eur J Endocrinol 161:189–193CrossRefPubMed
36.
Zurück zum Zitat Rolighed L, Rejnmark L, Sikjaer T, Heickendorff L, Vestergaard P, Mosekilde L, Christiansen P (2014) Vitamin D treatment in primary hyperparathyroidism: a randomized placebo controlled trial. J Clin Endocrinol Metab 99:1072–1080CrossRefPubMed Rolighed L, Rejnmark L, Sikjaer T, Heickendorff L, Vestergaard P, Mosekilde L, Christiansen P (2014) Vitamin D treatment in primary hyperparathyroidism: a randomized placebo controlled trial. J Clin Endocrinol Metab 99:1072–1080CrossRefPubMed
37.
Zurück zum Zitat Kantorovich V, Gacad MA, Seeger LL, Adams JS (2000) Bone mineral density increases with vitamin D repletion in patients with coexistent vitamin D insufficiency and primary hyperparathyroidism. J Clin Endocrinol Metab 85:3541–3543PubMed Kantorovich V, Gacad MA, Seeger LL, Adams JS (2000) Bone mineral density increases with vitamin D repletion in patients with coexistent vitamin D insufficiency and primary hyperparathyroidism. J Clin Endocrinol Metab 85:3541–3543PubMed
38.
Zurück zum Zitat Bilezikian JP, Meng X, Shi Y, Silverberg SJ (2000) Primary hyperparathyroidism in women: a tale of two cities—New York and Beijing. Int J Fertil Womens Med 45:158–165PubMed Bilezikian JP, Meng X, Shi Y, Silverberg SJ (2000) Primary hyperparathyroidism in women: a tale of two cities—New York and Beijing. Int J Fertil Womens Med 45:158–165PubMed
39.
Zurück zum Zitat Sempos CT, Vesper HW, Phinney KW, Thienpont LM, Coates PM (2012) Vitamin D status as an international issue: national surveys and the problem of standardization. Scand J Clin Lab Invest Suppl 243:32–40PubMed Sempos CT, Vesper HW, Phinney KW, Thienpont LM, Coates PM (2012) Vitamin D status as an international issue: national surveys and the problem of standardization. Scand J Clin Lab Invest Suppl 243:32–40PubMed
40.
Zurück zum Zitat Lensmeyer GL, Wiebe DA, Binkley N, Drezner MK (2006) HPLC method for 25-hydroxyvitamin D measurement: comparison with contemporary assays. Clin Chem 52:1120–1126CrossRefPubMed Lensmeyer GL, Wiebe DA, Binkley N, Drezner MK (2006) HPLC method for 25-hydroxyvitamin D measurement: comparison with contemporary assays. Clin Chem 52:1120–1126CrossRefPubMed
41.
Zurück zum Zitat Lips P, Chapuy MC, Dawson-Hughes B, Pols HA, Holick MF (1999) An international comparison of serum 25-hydroxyvitamin D measurements. Osteoporos Int 9:394–397CrossRefPubMed Lips P, Chapuy MC, Dawson-Hughes B, Pols HA, Holick MF (1999) An international comparison of serum 25-hydroxyvitamin D measurements. Osteoporos Int 9:394–397CrossRefPubMed
Metadaten
Titel
Low vitamin D levels have become less common in primary hyperparathyroidism
verfasst von
M. D. Walker
E. Cong
J. A. Lee
A. Kepley
C. Zhang
D. J. McMahon
J. P. Bilezikian
S. J. Silverberg
Publikationsdatum
01.12.2015
Verlag
Springer London
Erschienen in
Osteoporosis International / Ausgabe 12/2015
Print ISSN: 0937-941X
Elektronische ISSN: 1433-2965
DOI
https://doi.org/10.1007/s00198-015-3199-6

Weitere Artikel der Ausgabe 12/2015

Osteoporosis International 12/2015 Zur Ausgabe

Arthropedia

Grundlagenwissen der Arthroskopie und Gelenkchirurgie. Erweitert durch Fallbeispiele, Videos und Abbildungen. 
» Jetzt entdecken

Update Orthopädie und Unfallchirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.